Phase II Clinical Clical of the Pure Protein Derivatives of BCG
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: Purified Protein Derivative of BCG（BCG-PPD）
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06975774
- Locations
- 🇨🇳
The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China
Clinical Trials of Quadrivalent Influenza Vaccine
Phase 1
Recruiting
- Conditions
- Influenza, Human
- Interventions
- Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose)Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose)Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose)Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose)Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 620
- Registration Number
- NCT06824519
- Locations
- 🇨🇳
Hebei Province Centers for Disease Control and Prevention, Shijiazhuang, Hebei, China
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
Phase 3
Recruiting
- Conditions
- BCG
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT06747455
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of USTC, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
Phase 3
Active, not recruiting
- Conditions
- Acute Gastroenteropathy Due to Norovirus
- Interventions
- Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 6600
- Registration Number
- NCT06524947
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Hunan Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China
BCG for Therapeutic Use Phase I Clinical Trial
Phase 1
Recruiting
- Conditions
- Non-muscular Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06100653
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)
Phase 3
Completed
- Conditions
- Rabies Vaccine Adverse Reaction
- Interventions
- Biological: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose programBiological: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose programBiological: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose programBiological: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 1880
- Registration Number
- NCT06078423
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
Phase 1
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: PlaceboBiological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06043388
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Not Applicable
Not yet recruiting
- Conditions
- Coronavirus
- Interventions
- Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)Biological: Recombinant novel coronavirus protein vaccine (CHO cells)
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06025812
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Phase 3
Recruiting
- Conditions
- Latent Tuberculosis Infection
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 780
- Registration Number
- NCT05899179
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Changsha Central Hospital, Changsha, Hu Nan, China
🇨🇳The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
Not Applicable
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant Novel Coronavirus vaccine (CHO Cells)
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05895110
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath